Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06818682 | Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial(RELAX) | recruiting | Phase 2 | 206 | Tata Memorial CentreOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06838520 | Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer | not yet recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 20, 2025 |
| clinicaltrials |
| NCT06242119 | Clinical Application of the J-PET Scanner Prototype(JPET2Clinic) | recruiting | — | 25 | Jagiellonian UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06820606 | Comparing Rezum and Urolift | recruiting | N/A | 120 | Chinese University of Hong KongOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT06828003 | Feasibility of a Remotely-Delivered Resistance Training Program for Cognitive Function in Men Living With and Beyond Prostate Cancer | not yet recruiting | N/A | 30 | University of TorontoOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02302105 | Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer(POP-RT) | active not recruiting | N/A | 224 | Tata Memorial CentreOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06259279 | High Impact Training to Patients with Prostate Cancer and Bone Metastases(HIP) | recruiting | N/A | 102 | Copenhagen University Hospital at HerlevOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06612047 | Comparison of 5.0T and 3.0T Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer(5TbpMRI) | recruiting | — | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06737588 | The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer | recruiting | — | 600 | Anhui Provincial HospitalOTHER_GOV | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06783127 | Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer(COROS) | recruiting | — | 3,000 | Santa Chiara HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06820333 | Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer | recruiting | — | 200 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02176902 | Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer | active not recruiting | N/A | 107 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06449781 | 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer(PSMA-ADJUVO) | recruiting | Phase 2 | 200 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03763253 | Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms(IP2-ATLANTA) | active not recruiting | Phase 2 | 433 | Imperial College LondonOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04992728 | Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI | recruiting | — | 100 | University of California, San DiegoOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06785441 | Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing | recruiting | — | 180 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05381103 | PSMA-PET to Guide Prostatectomy | recruiting | Phase 2 / Phase 3 | 288 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06468332 | Artificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Cancer(PRISM-AI) | recruiting | — | 400 | Azienda Ospedaliero Universitaria Maggiore della CaritaOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT00223145 | Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone(PCS III) | active not recruiting | Phase 3 | 600 | Abdenour NabidOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT00223171 | Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers(PCS IV) | active not recruiting | Phase 3 | 630 | Université de SherbrookeOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05348577 | Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)(CAPItello280) | active not recruiting | Phase 3 | 1,035 | AstraZenecaINDUSTRY | 22 | Jan 27, 2025 | clinicaltrials |
| NCT06723665 | The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients | enrolling by invitation | N/A | 50 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06784986 | Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study.(ARCO2) | recruiting | Phase 4 | 200 | Brazilian Institute of Robotic SurgeryOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06554587 | Investigation of Three Biomarkers for the Detection of Prostate Cancer | recruiting | — | 137 | Medtechtomarket Consulting LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06773598 | Validation of a Machine Learning Model Based on MR for the Prediction of Prostate Cancer | recruiting | — | 1,100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774781 | Assessment of ADC Values and Radiomics Characteristics With a MRI of the Prostate to Identify Tumor Lesions | recruiting | — | 120 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04009967 | Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning(PICT-01) | active not recruiting | Phase 2 | 30 | CHU de Quebec-Universite LavalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06772116 | Focal Therapy in Localized Prostate Cancer: a Prospective Registry(JR) | not yet recruiting | — | 1,000 | Institut Mutualiste MontsourisOTHER | 0 | Jan 13, 2025 | clinicaltrials |
| NCT06768255 | Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC(mCRPC) | not yet recruiting | Phase 3 | 400 | Ding-Wei YeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT05479578 | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 7 | Rashmi Verma, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06762925 | Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment | not yet recruiting | — | 450 | Xijing HospitalOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT06756334 | Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis | recruiting | Early Phase 1 | 30 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 3, 2025 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 13 | Dec 31, 2024 | clinicaltrials |
| NCT06398613 | Preoperative PSMA PET/CT As Triage for EPLND in Patients Scheduled for RALP (PrePSMA)(PrePSMA) | recruiting | N/A | 600 | Oslo University HospitalOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06748456 | A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice | recruiting | N/A | 50 | University of CopenhagenOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06640959 | Chronic Radiation Induced Bowel Toxicity Study(CRIBS) | recruiting | — | 50 | The Christie NHS Foundation TrustOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02807805 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 37 | Mamta ParikhOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06696326 | A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer | recruiting | N/A | 100 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05989854 | The Remote Study: Investigating the Effects or Online Exercise on Quality of Life in Men With Prostate Cancer | recruiting | N/A | 50 | University of SurreyOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06736054 | A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer | recruiting | Phase 1 | 8 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health(COACH) | recruiting | N/A | 625 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05547061 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | active not recruiting | Phase 1 / Phase 2 | 91 | Cellbion Co., Ltd.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 21, 2025source: clinicaltrials